Xing Zhang Selected Research

formononetin

1/2018	Differential ability of formononetin to stimulate proliferation of endothelial cells and breast cancer cells via a feedback loop involving MicroRNA-375, RASD1, and ERα.
3/2017	Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of miR-21 and PTEN.
3/2016	Formononetin promotes proliferation that involves a feedback loop of microRNA-375 and estrogen receptor alpha in estrogen receptor-positive cells.
1/2014	Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway.
12/2013	Formononetin induces the mitochondrial apoptosis pathway in prostate cancer cells via downregulation of the IGF-1/IGF-1R signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xing Zhang Research Topics

Disease

169	Neoplasms (Cancer) 07/2022 - 02/2002
31	Infections 09/2022 - 07/2004
25	Stomach Neoplasms (Stomach Cancer) 01/2022 - 01/2004
22	Inflammation (Inflammations) 11/2022 - 11/2010
20	Breast Neoplasms (Breast Cancer) 12/2022 - 09/2006
18	Neoplasm Metastasis (Metastasis) 12/2022 - 02/2005
14	Carcinoma (Carcinomatosis) 04/2020 - 05/2004
13	Fibrosis (Cirrhosis) 04/2022 - 04/2009
13	Hypoxia (Hypoxemia) 01/2022 - 09/2006
13	Pulmonary Tuberculosis 12/2019 - 01/2012
11	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 08/2005
11	Carcinogenesis 01/2022 - 01/2013
11	Virus Diseases (Viral Diseases) 01/2022 - 01/2018
11	Malignant Mesothelioma 01/2021 - 05/2014
10	Pain (Aches) 01/2022 - 01/2016
10	Lung Neoplasms (Lung Cancer) 01/2022 - 02/2002
9	Cardiovascular Diseases (Cardiovascular Disease) 12/2022 - 05/2010
9	Sarcoma (Soft Tissue Sarcoma) 05/2022 - 05/2015
9	Obesity 04/2022 - 04/2015
9	Wounds and Injuries (Trauma) 01/2022 - 06/2013
9	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2002
9	Ischemia 01/2021 - 01/2008
8	Reperfusion Injury 01/2022 - 01/2013
8	Myocardial Infarction 01/2022 - 08/2006
8	Hepatocellular Carcinoma (Hepatoma) 09/2021 - 01/2017
7	Stroke (Strokes) 11/2022 - 10/2019
7	Hypertension (High Blood Pressure) 03/2022 - 01/2018
7	Insulin Resistance 01/2022 - 06/2014
7	COVID-19 01/2022 - 05/2020
7	Prostatic Neoplasms (Prostate Cancer) 03/2021 - 12/2013
7	Mesothelioma 11/2020 - 01/2004
7	Poisoning 09/2020 - 06/2008
7	Melanoma (Melanoma, Malignant) 01/2020 - 12/2012
7	Nasopharyngeal Carcinoma 07/2016 - 01/2007
6	Colonic Neoplasms (Colon Cancer) 07/2022 - 06/2008
6	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022 - 01/2013
6	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 01/2013
6	Body Weight (Weight, Body) 01/2021 - 05/2004
6	Tuberculosis (Tuberculoses) 12/2020 - 04/2012
6	Sepsis (Septicemia) 01/2020 - 01/2015
6	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 09/2014 - 10/2010
5	Ischemic Stroke 11/2022 - 03/2014
5	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2019
5	Type 2 Diabetes Mellitus (MODY) 01/2021 - 03/2016

Drug/Important Bio-Agent (IBA)

56	Proteins (Proteins, Gene)FDA Link 07/2022 - 12/2002
44	Biomarkers (Surrogate Marker)IBA 03/2022 - 11/2007
25	Pharmaceutical PreparationsIBA 12/2022 - 07/2009
22	Messenger RNA (mRNA)IBA 01/2022 - 10/2005
19	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 07/2006
19	Circular RNAIBA 01/2022 - 12/2017
19	Biological ProductsIBA 01/2022 - 07/2009
18	MicroRNAs (MicroRNA)IBA 10/2021 - 01/2013
15	AsbestosIBA 01/2021 - 11/2003
12	Long Noncoding RNAIBA 10/2021 - 11/2017
12	Transcription Factors (Transcription Factor)IBA 02/2021 - 08/2012
11	CytokinesIBA 01/2022 - 12/2008
9	RNA (Ribonucleic Acid)IBA 05/2022 - 06/2009
8	Peptides (Polypeptides)IBA 01/2022 - 10/2014
8	Insulin (Novolin)FDA Link 01/2019 - 01/2013
7	Adenosine Triphosphate (ATP)IBA 01/2021 - 09/2014
7	ErbB Receptors (EGF Receptor)IBA 08/2020 - 08/2005
7	CollagenIBA 01/2020 - 06/2003
7	Therapeutic UsesIBA 01/2020 - 01/2012
7	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 01/2013
6	Interleukin-6 (Interleukin 6)IBA 11/2022 - 07/2015
6	Indicators and Reagents (Reagents)IBA 05/2022 - 02/2002
6	LipidsIBA 04/2022 - 03/2007
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2008
6	7,3'-dihydroxy-4'-methoxyisoflavoneIBA 01/2022 - 01/2014
6	Phosphotransferases (Kinase)IBA 01/2022 - 01/2008
6	EnzymesIBA 03/2021 - 02/2002
6	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 07/2008
6	GoldIBA 01/2021 - 02/2016
6	salicylhydroxamic acid (SHAM)IBA 01/2019 - 07/2013
5	LDL CholesterolIBA 11/2022 - 03/2013
5	Triglycerides (Triacylglycerol)IBA 07/2022 - 03/2007
5	HDL CholesterolIBA 07/2022 - 03/2013
5	Oxygen (Dioxygen)IBA 01/2022 - 01/2020
5	Immune Checkpoint InhibitorsIBA 01/2022 - 09/2015
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 06/2015
5	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 03/2015
5	NitrogenIBA 01/2022 - 01/2014
5	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2019
5	Tumor Biomarkers (Tumor Markers)IBA 01/2022 - 02/2002
5	Fatty Acids (Saturated Fatty Acids)IBA 12/2021 - 06/2015
5	Polysaccharides (Glycans)IBA 04/2021 - 02/2016
5	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2021 - 12/2008
5	Estrogens (Estrogen)FDA Link 01/2021 - 06/2008
5	CalciumIBA 01/2021 - 12/2017
5	CarbonIBA 12/2020 - 12/2018
5	VaccinesIBA 05/2020 - 07/2006
5	formononetinIBA 01/2018 - 12/2013

Therapy/Procedure

49	Therapeutics 03/2022 - 12/2007
29	Drug Therapy (Chemotherapy) 01/2022 - 10/2008
9	Lasers (Laser) 01/2022 - 01/2011
9	Transplantation 07/2021 - 08/2006
8	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2022 - 09/2014
7	Immunotherapy 01/2022 - 01/2018
7	Photothermal Therapy 01/2021 - 12/2016
5	Aftercare (After-Treatment) 01/2020 - 06/2003